Ionis Pharmaceuticals Inc. (IONS) Financial Statements (2025 and earlier)

Company Profile

Business Address 2855 GAZELLE COURT
CARLSBAD, CA 92010
State of Incorp. CA
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2,078,6862,206,2162,331,2012,235,5822,385,3882,346,781
Cash and cash equivalents293,993348,889399,266352,060424,790309,031
Short-term investments1,784,6931,857,3271,931,9351,883,5221,960,5982,037,750
Inventory, net of allowances, customer advances and progress billings28,72330,25928,42525,63425,53822,200
Inventory28,72330,25928,42525,63425,53822,200
Contract with customer, asset, after allowance for credit loss27,2595,14097,778142,35927,95613,914
Other current assets194,715174,060184,449181,075177,872159,724
Total current assets:2,329,3832,415,6752,641,8532,584,6502,616,7542,542,619
Noncurrent Assets
Operating lease, right-of-use asset166,939169,431171,896174,310176,718179,148
Property, plant and equipment75,90272,79571,04370,92891,63485,158
Long-term investments and receivables460,837     
Long-term investments460,837     
Other noncurrent assets118,904106,027105,280104,08386,02578,296
Other undisclosed noncurrent assets(460,837)     
Total noncurrent assets:361,745348,253348,219349,321354,377342,602
TOTAL ASSETS:2,691,1282,763,9282,990,0722,933,9712,971,1312,885,221
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities123,573119,130173,921124,583128,766123,201
Accounts payable9,24313,08226,0275,61524,02110,499
Accrued liabilities114,330106,048147,894118,968104,745112,702
Deferred revenue94,066130,406151,128204,82496,25292,335
Debt44,42244,377157   
Other liabilities8,7999,9888,8319,9528,9038,239
Other undisclosed current liabilities35,30223,747114,05364,85154,05435,446
Total current liabilities:306,162327,648448,090404,210287,975259,221
Noncurrent Liabilities
Long-term debt and lease obligation   1,241,004  8,811
Long-term debt, excluding current maturities   1,241,004  8,811
Liabilities, other than long-term debt396,912425,562412,059471,111445,854457,460
Deferred revenue188,701215,088241,184249,272254,398272,973
Other liabilities41,77341,800 48,80116,4367,487
Operating lease, liability166,438168,674170,875173,038175,020177,000
Other undisclosed noncurrent liabilities1,724,3561,714,203502,2331,743,1901,809,0011,673,159
Total noncurrent liabilities:2,121,2682,139,7652,155,2962,214,3012,254,8552,139,430
Total liabilities:2,427,4302,467,4132,603,3862,618,5112,542,8302,398,651
Equity
Equity, attributable to parent263,698296,515386,686315,460428,301486,570
Common stock146146144143143143
Additional paid in capital2,303,3692,270,0472,215,0982,148,0022,118,3092,089,358
Accumulated other comprehensive loss(34,838)(34,964)(32,645)(46,037)(50,913)(48,983)
Accumulated deficit(2,004,979)(1,938,714)(1,795,911)(1,786,648)(1,639,238)(1,553,948)
Total equity:263,698296,515386,686315,460428,301486,570
TOTAL LIABILITIES AND EQUITY:2,691,1282,763,9282,990,0722,933,9712,971,1312,885,221

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Revenues225,250119,497324,505144,207188,411130,524
Cost of revenue(226,228)(215,594)(257,989)(217,521)(232,464)(198,104)
Gross profit:(978)(96,097)66,516(73,314)(44,053)(67,580)
Operating expenses(65,113)(53,416)(72,639)(69,951)(46,142)(46,568)
Operating loss:(66,091)(149,513)(6,123)(143,265)(90,195)(114,148)
Nonoperating income22,67628,89525,92424,43932,69318,328
Investment income, nonoperating22,06628,61825,52521,99221,51018,098
Other nonoperating income6102773992,44711,183230
Interest and debt expense  (4,151)(4,558)(4,203)(2,291)(1,608)
Income (loss) from continuing operations before equity method investments, income taxes:(43,415)(124,769)15,243(123,029)(59,793)(97,428)
Other undisclosed loss from continuing operations before income taxes(22,786)(17,959)(18,010)(17,779)(17,655)(15,515)
Loss from continuing operations before income taxes:(66,201)(142,728)(2,767)(140,808)(77,448)(112,943)
Income tax expense (benefit)(64)(75)(6,496)(6,602)(7,842)(11,380)
Net loss available to common stockholders, diluted:(66,265)(142,803)(9,263)(147,410)(85,290)(124,323)

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net loss:(66,265)(142,803)(9,263)(147,410)(85,290)(124,323)
Comprehensive loss:(66,265)(142,803)(9,263)(147,410)(85,290)(124,323)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent126(2,319)13,3924,876(1,930)8,497
Comprehensive income (loss), net of tax, attributable to parent:(66,139)(145,122)4,129(142,534)(87,220)(115,826)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: